# NVO catalysts: NOVO NORDISK A S PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/nvo/catalysts

> NOVO NORDISK A S (NVO) has 96 upcoming catalysts. The next is the NNC0662-0419 topline data readout, Dec 2026 to Mar 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | NOVO NORDISK A S |
| Ticker | NVO (NYSE) |
| SEC CIK | 353278 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/nvo |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 21, 2016 | [Xultophy 100/3.6 (insulin degludec; liraglutide) FDA approval](https://sec-api.dev/pdufa/insulin-degludec-liraglutide) | NVO |  | completed, approved | "BLA208583 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20161121, review_priority STANDARD; sponsor_name NOVO; product XULTOPHY 100/3.6 (INSULIN DEGLUDEC; LIRAGLUTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA208583%22)) |
| September 29, 2017 | [Fiasp Penfill (insulin aspart) FDA approval](https://sec-api.dev/pdufa/insulin-aspart) | NVO |  | completed, approved | "BLA208751 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20170929, review_priority STANDARD; sponsor_name NOVO; product FIASP PENFILL (INSULIN ASPART)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA208751%22)) |
| December 5, 2017 | [Wegovy (semaglutide) FDA approval](https://sec-api.dev/pdufa/semaglutide) | NVO |  | completed, approved | "NDA209637 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20171205, review_priority STANDARD; sponsor_name NOVO; product OZEMPIC (SEMAGLUTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209637%22)) |
| September 20, 2019 | [Wegovy (semaglutide) FDA approval](https://sec-api.dev/pdufa/semaglutide) | NVO |  | completed, approved | "NDA213051 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20190920, review_priority PRIORITY; sponsor_name NOVO; product OZEMPIC (SEMAGLUTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213051%22)) |
| January 16, 2020 | [Wegovy (semaglutide) FDA approval](https://sec-api.dev/pdufa/semaglutide) | NVO |  | completed, approved | "NDA213182 ORIG-1 (Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval): submission_status AP, submission_status_date 20200116, review_priority STANDARD; sponsor_name NOVO NORDISK INC; product RYBELSUS (SEMAGLUTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213182%22)) |
| January 16, 2020 | [Wegovy (semaglutide) label expansion decision](https://sec-api.dev/pdufa/semaglutide) | NVO |  | completed, approved | "NDA209637 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20200116, review_priority STANDARD; sponsor_name NOVO; product OZEMPIC (SEMAGLUTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209637%22)) |
| March 25, 2020 | [Saxenda (liraglutide) label expansion decision](https://sec-api.dev/pdufa/liraglutide) | NVO |  | completed, approved | "NDA206321 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20200325, review_priority STANDARD; sponsor_name NOVO; product SAXENDA (LIRAGLUTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA206321%22)) |
| August 28, 2020 | [Sogroya (somapacitan-beco) FDA approval](https://sec-api.dev/pdufa/somapacitan-beco) | NVO |  | completed, approved | "BLA761156 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20200828, review_priority STANDARD; sponsor_name NOVO NORDISK INC; product SOGROYA (SOMAPACITAN-BECO)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761156%22)) |
| December 4, 2020 | [Saxenda (liraglutide) label expansion decision](https://sec-api.dev/pdufa/liraglutide) | NVO |  | completed, approved | "NDA206321 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20201204, review_priority STANDARD; sponsor_name NOVO; product SAXENDA (LIRAGLUTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA206321%22)) |
| June 4, 2021 | [Wegovy (semaglutide) FDA approval](https://sec-api.dev/pdufa/semaglutide) | NVO |  | completed, approved | "NDA215256 ORIG-1 (Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated): submission_status AP, submission_status_date 20210604, review_priority PRIORITY; sponsor_name NOVO; product WEGOVY (SEMAGLUTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215256%22)) |
| March 28, 2022 | [Wegovy (semaglutide) label expansion decision](https://sec-api.dev/pdufa/semaglutide) | NVO |  | completed, approved | "NDA209637 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20220328, review_priority STANDARD; sponsor_name NOVO; product OZEMPIC (SEMAGLUTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209637%22)) |
| July 1, 2022 | [Tresiba (insulin degludec) label expansion decision](https://sec-api.dev/pdufa/insulin-degludec) | NVO |  | completed, approved | "BLA203314 SUPPL-20 (Efficacy): submission_status AP, submission_status_date 20220701, review_priority STANDARD; sponsor_name NOVO; product TRESIBA (INSULIN DEGLUDEC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA203314%22)) |
| December 23, 2022 | [Wegovy (semaglutide) label expansion decision](https://sec-api.dev/pdufa/semaglutide) | NVO |  | completed, approved | "NDA215256 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20221223, review_priority PRIORITY; sponsor_name NOVO; product WEGOVY (SEMAGLUTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215256%22)) |
| April 24, 2023 | [Alhemo (concizumab-mtci) complete response letter (CRL)](https://sec-api.dev/pdufa/concizumab-mtci) | NVO |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22761315_2025_Orig1s000OtherActionLtrs.pdf%22)) |
| April 28, 2023 | [Sogroya (somapacitan-beco) label expansion decision](https://sec-api.dev/pdufa/somapacitan-beco) | NVO |  | completed, approved | "BLA761156 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20230428, review_priority STANDARD; sponsor_name NOVO NORDISK INC; product SOGROYA (SOMAPACITAN-BECO)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761156%22)) |
| July 21, 2023 | [Wegovy (semaglutide) label expansion decision](https://sec-api.dev/pdufa/semaglutide) | NVO |  | completed, approved | "NDA215256 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20230721, review_priority STANDARD; sponsor_name NOVO; product WEGOVY (SEMAGLUTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215256%22)) |
| September 29, 2023 | [Rivfloza (nedosiran sodium) FDA approval](https://sec-api.dev/pdufa/nedosiran) | NVO |  | completed, approved | "Rivfloza \| nedosiran \| 9/29/2023 \| To lower urinary oxalate levels in patients 9 years and older with primary hyperoxaluria type 1 and relatively preserved kidney functionDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)) |
| March 8, 2024 | [Wegovy (semaglutide) label expansion decision](https://sec-api.dev/pdufa/semaglutide) | NVO |  | completed, approved | "NDA215256 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20240308, review_priority PRIORITY; sponsor_name NOVO; product WEGOVY (SEMAGLUTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215256%22)) |
| July 10, 2024 | [Awiqli Flextouch (insulin icodec) complete response letter (CRL)](https://sec-api.dev/pdufa/insulin-icodec) | NVO |  | completed, complete response letter | "We have completed the review of BLA 761326/Original 1 and BLA 761326/Original 2, as amended, and have determined that we cannot approve these applications in their present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761326_20240710.pdf%22)) |
| Nov 2024 | [NN1644 trial start](https://sec-api.dev/pdufa/nn1644) | NVO |  | completed | "In November 2024, Novo Nordisk initiated a phase 1 trial with a subcutaneously administrated glucose-sensitive insulin NN1644." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/353278/000162828025003924/caq42024.htm)) |
| November 27, 2024 | [Wegovy (semaglutide) label expansion decision](https://sec-api.dev/pdufa/semaglutide) | NVO |  | completed, approved | "NDA215256 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20241127, review_priority STANDARD; sponsor_name NOVO; product WEGOVY (SEMAGLUTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215256%22)) |
| Dec 2024 | [Rybelsus (rybelsus) NDA/BLA submission](https://sec-api.dev/pdufa/rybelsus) | NVO | type 2 diabetes and established cardiovascular disease and/or chronic kidney disease | completed | "In December 2024 and January 2025, Novo Nordisk submitted a supplemental New Drug Application (sNDA) to the US FDA and a Type II variant application to the EMA, respectively, for Rybelsus® for the indication of reducing the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack or non-fatal stroke) in people with type 2 diabetes and established cardiovascular disease and/or chronic kidney disease." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/353278/000162828025003924/caq42024.htm)) |
| Dec 2024 | [Wegovy (semaglutide) trial start](https://sec-api.dev/pdufa/semaglutide) | NVO |  | completed | "In December 2024, Novo Nordisk initiated a phase 2 trial with a subcutaneous once-weekly dual GIP/GLP-1 agonist in approximately 450 people with chronic kidney disease, with or without type 2 diabetes and with overweight or obesity." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/353278/000162828025003924/caq42024.htm)) |
| Dec 2024 | [Ozempic® (ozempic) NDA/BLA submission](https://sec-api.dev/pdufa/ozempic) | NVO |  | completed | "In December 2024 and January 2025, Novo Nordisk submitted a supplemental New Drug Application (sNDA) to the US FDA and a Type II variant application to the EMA, respectively, for Ozempic® for the indication of peripheral artery disease." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/353278/000162828025003924/caq42024.htm)) |
| December 9, 2024 | [Wegovy (semaglutide) label expansion decision](https://sec-api.dev/pdufa/semaglutide) | NVO |  | completed, approved | "NDA213051 SUPPL-20 (Efficacy): submission_status AP, submission_status_date 20241209, review_priority STANDARD; sponsor_name NOVO; product OZEMPIC (SEMAGLUTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213051%22)) |
| December 20, 2024 | [Alhemo (concizumab-mtci) FDA approval](https://sec-api.dev/pdufa/concizumab-mtci) | NVO | For routine prophylaxis to prevent bleeding episodes in hemophilia A and B | completed, approved | "Alhemo \| concizumab-mtci \| 12/20/2024 \| For routine prophylaxis to prevent bleeding episodes in hemophilia A and BDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)) |
| January 28, 2025 | [Wegovy (semaglutide) label expansion decision](https://sec-api.dev/pdufa/semaglutide) | NVO |  | completed, approved | "NDA209637 SUPPL-25 (Efficacy): submission_status AP, submission_status_date 20250128, review_priority STANDARD; sponsor_name NOVO; product OZEMPIC (SEMAGLUTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209637%22)) |
| Feb 2025 | [PDS290 NDA/BLA submission](https://sec-api.dev/pdufa/pds290) | NVO |  | completed | "In February 2025, Novo Nordisk submitted a Supplemental New Drug Application (sNDA) to the US FDA for PDS290 device variant for Wegovy®." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/353278/000162828025022877/caq12025.htm)) |
| March 27, 2025 | [Rivfloza (nedosiran sodium) label expansion decision](https://sec-api.dev/pdufa/nedosiran) | NVO |  | completed, approved | "NDA215842 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20250327, review_priority STANDARD; sponsor_name NOVO; product RIVFLOZA (NEDOSIRAN SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215842%22)) |
| May 8, 2025 | [Awiqli Flextouch (insulin icodec) primary completion](https://sec-api.dev/pdufa/insulin-icodec) | NVO | Diabetes, Type 2 | completed | "NCT06340854 (A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-08 (ACTUAL); Lead Sponsor Novo Nordisk A/S; Results First Posted 2026-07-02." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06340854)) |
| May 27, 2025 | [Icosema primary completion](https://sec-api.dev/pdufa/icosema) | NVO | Type 2 Diabetes | completed | "NCT06269107 (A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-27 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06269107)) |
| Jun 2025 | [Wegovy (semaglutide) trial start](https://sec-api.dev/pdufa/semaglutide) | NVO | obesity | completed | "In June 2025, Novo Nordisk initiated a phase 3b trial, REDEFINE 11, for CagriSema in people living with obesity." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/353278/000162828025038087/caq22025.htm)) |
| Jul 2025 | [NN6705 trial start](https://sec-api.dev/pdufa/nn6705) | NVO |  | completed | "In July 2025, Novo Nordisk initiated a phase 1 trial with an oral NRLP3 inhibitor (NN6705), aiming for oral treatment in a broad range of liver, kidney and cardiometabolic diseases." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/353278/000162828025038087/caq22025.htm)) |
| July 20, 2025 | [Dasiglucagon primary completion](https://sec-api.dev/pdufa/dasiglucagon) | NVO | Diabetes Mellitus, Type 1 | completed | "NCT06588504 (Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-20 (ACTUAL); Lead Sponsor Novo Nordisk A/S; Results First Posted 2026-11-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06588504)) |
| July 24, 2025 | [Ndec - oral decitabine-tetrahydrouridine primary completion](https://sec-api.dev/pdufa/ndec-oral-decitabine-tetrahydrouridine) | NVO | Sickle Cell Disease | completed | "NCT05405114 (Research Study Investigating How Well NDec Works in People With Sickle Cell Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-24 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05405114)) |
| July 31, 2025 | [Alhemo (concizumab) FDA approval](https://sec-api.dev/pdufa/concizumab) | NVO |  | completed, approved | "BLA761428 ORIG-1 (Type 9 - New indication submitted as distinct BLA, consolidated): submission_status AP, submission_status_date 20250731, review_priority STANDARD; sponsor_name NOVO NORDISK INC; product ALHEMO (CONCIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761428%22)) |
| August 15, 2025 | [Wegovy (semaglutide) label expansion decision](https://sec-api.dev/pdufa/semaglutide) | NVO | moderate to advanced liver fibrosis | completed, approved | "Bagsv&aelig;rd, Denmark, 15 August 2025 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/353278/000117184325005454/f6k_081525.htm)) |
| Sep 2025 | [Denecimig NDA/BLA submission](https://sec-api.dev/pdufa/denecimig) | NVO | haemophilia A in adult and paediatric patients | completed | "Novo submitted a BLA for denecimig for the treatment of haemophilia A in adult and paediatric patients to the US FDA for review in September 2025, with an anticipated regulatory decision in the third quarter of 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/353278/000117184326006374/f6k_100226.htm)) |
| September 9, 2025 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Type 2 Diabetes | completed | "NCT06323161 (A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-09 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06323161)) |
| September 15, 2025 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Early Alzheimer´s Disease | completed | "NCT04777409 (A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-15 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04777409)) |
| September 16, 2025 | [Semagludtide primary completion](https://sec-api.dev/pdufa/semagludtide) | NVO | Early Alzheimer's Disease | completed | "NCT04777396 (A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-16 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04777396)) |
| September 19, 2025 | [NNC0519-0130 primary completion](https://sec-api.dev/pdufa/nnc0519-0130) | NVO | Diabetes Mellitus, Type 2 | completed | "NCT06326047 (A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-19 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06326047)) |
| September 24, 2025 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Chronic Kidney Disease; Type 2 Diabetes; Obesity | completed | "NCT06131372 (A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-24 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06131372)) |
| September 30, 2025 | [Wegovy (semaglutide) FDA approval](https://sec-api.dev/pdufa/semaglutide) | NVO |  | completed, approved | "•Within R&D, Novo Nordisk announced that the US FDA had approved an indication for Wegovy® for the treatment of MASH." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/353278/000035327825000005/caq32025.htm)) |
| October 1, 2025 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Type 2 Diabetes | completed | "NCT06323174 (A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-01 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06323174)) |
| October 1, 2025 | [Nnc0487-0111 subcutanous primary completion](https://sec-api.dev/pdufa/nnc0487-0111-subcutanous) | NVO | Type 2 Diabetes (T2D) | completed | "NCT06542874 (A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-01 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06542874)) |
| October 15, 2025 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Obesity | completed | "NCT05726227 (A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-15 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05726227)) |
| October 17, 2025 | [Wegovy (semaglutide) label expansion decision](https://sec-api.dev/pdufa/semaglutide) | NVO |  | completed, approved | "NDA213051 SUPPL-24 (Efficacy): submission_status AP, submission_status_date 20251017, review_priority STANDARD; sponsor_name NOVO; product OZEMPIC (SEMAGLUTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213051%22)) |
| November 19, 2025 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Type 2 Diabetes Mellitus | completed | "NCT06065540 (A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-19 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06065540)) |
| November 21, 2025 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Alcohol-related Liver Disease | completed | "NCT06409130 (Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-21 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06409130)) |
| November 21, 2025 | [Wegovy (semaglutide) label expansion decision](https://sec-api.dev/pdufa/semaglutide) | NVO |  | completed, approved | "NDA215256 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20251121, review_priority STANDARD; sponsor_name NOVO; product WEGOVY (SEMAGLUTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215256%22)) |
| December 8, 2025 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Obesity | completed | "NCT06131437 (A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-08 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06131437)) |
| December 22, 2025 | [Wegovy (semaglutide) FDA approval](https://sec-api.dev/pdufa/semaglutide) | NVO |  | completed, approved | "NDA218316 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20251222, review_priority STANDARD; sponsor_name NOVO; product WEGOVY (SEMAGLUTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218316%22)) |
| February 27, 2026 | [Sogroya (somapacitan-beco) label expansion decision](https://sec-api.dev/pdufa/somapacitan-beco) | NVO |  | completed, approved | "BLA761156 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20260227, review_priority STANDARD; sponsor_name NOVO NORDISK INC; product SOGROYA (SOMAPACITAN-BECO)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761156%22)) |
| March 4, 2026 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Type 2 Diabetes | completed | "NCT06221969 (A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-03-04 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06221969)) |
| March 9, 2026 | [Etavopivat primary completion](https://sec-api.dev/pdufa/etavopivat) | NVO | Sickle Cell Disease | completed | "NCT05725902 (Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-03-09 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05725902)) |
| March 19, 2026 | [Wegovy (semaglutide) FDA approval](https://sec-api.dev/pdufa/semaglutide) | NVO |  | completed, approved | "Bagsv&aelig;rd, Denmark, 19 March 2026 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Wegovy® HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight reduction long-term." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/353278/000117184326001813/f6k_031926.htm)) |
| March 19, 2026 | [Wegovy (semaglutide) label expansion decision](https://sec-api.dev/pdufa/semaglutide) | NVO |  | completed, approved | "NDA215256 SUPPL-29 (Efficacy): submission_status AP, submission_status_date 20260319, review_priority STANDARD; sponsor_name NOVO; product WEGOVY (SEMAGLUTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215256%22)) |
| March 26, 2026 | [Awiqli Flextouch (insulin icodec) FDA approval](https://sec-api.dev/pdufa/insulin-icodec) | NVO |  | completed, approved | "BLA761326 ORIG-2 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20260326, review_priority STANDARD; sponsor_name NOVO NORDISK INC; product AWIQLI FLEXTOUCH (INSULIN ICODEC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761326%22)) |
| March 27, 2026 | [Awiqli (awiqli) FDA approval](https://sec-api.dev/pdufa/awiqli) | NVO | type 2 diabetes | completed, approved | "Bagsv&aelig;rd, Denmark, 27 March 2026 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly, long-acting basal insulin, indicated as an adjunct to diet and exercise to improve glycaemic control (blood sugar) in adults living with type 2 diabetes." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/353278/000117184326001959/f6k_032626.htm)) |
| Q2 2026 | [UBT251 trial start](https://sec-api.dev/pdufa/ubt251) | NVO | type 2 diabetes | scheduled | "•Novo Nordisk expects to initiate the global phase 2 trial with UBT251 in people with type 2 diabetes in the second quarter of 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/353278/000035327826000018/caq12026.htm)) |
| April 21, 2026 | [Alhemo (concizumab) primary completion](https://sec-api.dev/pdufa/concizumab) | NVO | Haemophilia A and B With and Without Inhibitors | completed | "NCT05135559 (A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-21 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05135559)) |
| April 22, 2026 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Obesity | completed | "NCT06388187 (A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-22 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06388187)) |
| June 2, 2026 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Diabetes Mellitus, Type 2 | completed | "NCT06534411 (A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-02 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06534411)) |
| June 9, 2026 | [Ziltivekimab b primary completion](https://sec-api.dev/pdufa/ziltivekimab-b) | NVO | Cardiovascular Risk; Chronic Kidney Disease; Inflammation | completed | "NCT05021835 (ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-09 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05021835)) |
| June 26, 2026 | [Cagrisema (cagrilintide b and semaglutide i) primary completion](https://sec-api.dev/pdufa/cagrisema-cagrilintide-b-and-semaglutide-i) | NVO | Diabetes Mellitus, Type 2; Diabetic Peripheral Neuropathy | completed | "NCT06797869 (A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-06-26 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06797869)) |
| June 29, 2026 | [Oral semaglutide primary completion](https://sec-api.dev/pdufa/oral-semaglutide) | NVO | Type 2 Diabetes | completed | "NCT07271251 (A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-29 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07271251)) |
| July 2, 2026 | [Awiqli Flextouch (insulin icodec) topline data readout](https://sec-api.dev/pdufa/insulin-icodec) | NVO | Diabetes, Type 2 | completed | "NCT06340854 (A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-08 (ACTUAL); Lead Sponsor Novo Nordisk A/S; Results First Posted 2026-07-02." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06340854?tab=results)) |
| September 2026 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Chronic Kidney Disease | delayed | "NCT06717698 (A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-09-01 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06717698)) |
| Sep to Dec 2026 | [Wegovy (semaglutide) topline data readout](https://sec-api.dev/pdufa/semaglutide) | NVO | Chronic Kidney Disease | scheduled | "NCT06717698 (A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-09-01 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06717698)) |
| September 3, 2026 | [Ziltivekimab primary completion](https://sec-api.dev/pdufa/ziltivekimab) | NVO | Heart Failure | withdrawn | "NCT05636176 (A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-09-03 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05636176)) |
| October 2026 | [Ziltivekimab primary completion](https://sec-api.dev/pdufa/ziltivekimab) | NVO | Heart Failure; Systemic Inflammation | delayed | "NCT06200207 (A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-01 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06200207)) |
| Oct 2026 to Jan 2027 | [Ziltivekimab topline data readout](https://sec-api.dev/pdufa/ziltivekimab) | NVO | Heart Failure; Systemic Inflammation | scheduled | "NCT06200207 (A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-01 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06200207)) |
| October 23, 2026 | [Awiqli Flextouch (insulin icodec) label expansion decision](https://sec-api.dev/pdufa/insulin-icodec) | NVO |  | completed, approved | "BLA761326 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20261023, review_priority PRIORITY; sponsor_name NOVO NORDISK INC; product AWIQLI FLEXTOUCH (INSULIN ICODEC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761326%22)) |
| November 16, 2026 | [Dasiglucagon topline data readout](https://sec-api.dev/pdufa/dasiglucagon) | NVO | Diabetes Mellitus, Type 1 | completed | "NCT06588504 (Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-20 (ACTUAL); Lead Sponsor Novo Nordisk A/S; Results First Posted 2026-11-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06588504?tab=results)) |
| Dec 2026 to Mar 2027 | [NNC0662-0419 topline data readout](https://sec-api.dev/pdufa/nnc0662-0419) | NVO | Overweight; Obesity | scheduled | "NCT07184632 (A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07184632)) |
| December 2026 | [NNC0662-0419 primary completion](https://sec-api.dev/pdufa/nnc0662-0419) | NVO | Overweight; Obesity | scheduled | "NCT07184632 (A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07184632)) |
| Jan to Apr 2027 | [Ziltivekimab topline data readout](https://sec-api.dev/pdufa/ziltivekimab) | NVO | Cardiovascular Risk; Acute Myocardial Infarction (AMI) | scheduled | "NCT06118281 (ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-29 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06118281)) |
| Jan to Apr 2027 | [Awiqli Flextouch (insulin icodec) topline data readout](https://sec-api.dev/pdufa/insulin-icodec) | NVO | Diabetes Mellitus, Type 1 | scheduled | "NCT07076199 (A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-25 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07076199)) |
| Jan to Apr 2027 | [UBT251 topline data readout](https://sec-api.dev/pdufa/ubt251) | NVO | Overweight; Obesity | scheduled | "NCT07395687 (A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-01-14 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07395687)) |
| January 2027 | [UBT251 primary completion](https://sec-api.dev/pdufa/ubt251) | NVO | Overweight; Obesity | scheduled | "NCT07395687 (A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-01-14 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07395687)) |
| January 2027 | [Awiqli Flextouch (insulin icodec) primary completion](https://sec-api.dev/pdufa/insulin-icodec) | NVO | Diabetes Mellitus, Type 1 | scheduled | "NCT07076199 (A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-25 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07076199)) |
| January 2027 | [Ziltivekimab primary completion](https://sec-api.dev/pdufa/ziltivekimab) | NVO | Cardiovascular Risk; Acute Myocardial Infarction (AMI) | scheduled | "NCT06118281 (ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-29 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06118281)) |
| March 2027 | [Cagrisema (cagrilintide b and semaglutide i) primary completion](https://sec-api.dev/pdufa/cagrisema-cagrilintide-b-and-semaglutide-i) | NVO | Obesity | scheduled | "NCT07011667 (A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-01 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07011667)) |
| Mar to Jun 2027 | [Cagrisema (cagrilintide b and semaglutide i) topline data readout](https://sec-api.dev/pdufa/cagrisema-cagrilintide-b-and-semaglutide-i) | NVO | Obesity | scheduled | "NCT07011667 (A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-01 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07011667)) |
| May to Aug 2027 | [CDR132L topline data readout](https://sec-api.dev/pdufa/cdr132l) | NVO | Heart Failure | scheduled | "NCT06979375 (A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05-16 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06979375)) |
| May to Aug 2027 | [Cagrilintide topline data readout](https://sec-api.dev/pdufa/cagrilintide) | NVO | Obesity; Overweight | scheduled | "NCT07220642 (Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-11 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07220642)) |
| May to Aug 2027 | [Cagrilintide topline data readout](https://sec-api.dev/pdufa/cagrilintide) | NVO | Overweight; Obesity; Type 2 Diabetes | scheduled | "NCT07220759 (Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-12 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07220759)) |
| May to Aug 2027 | [Cagrilintide topline data readout](https://sec-api.dev/pdufa/cagrilintide) | NVO | Overweight; Obesity | scheduled | "NCT07745504 (A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-18 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07745504)) |
| May 2027 | [Cagrilintide primary completion](https://sec-api.dev/pdufa/cagrilintide) | NVO | Obesity; Overweight | scheduled | "NCT07220642 (Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-11 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07220642)) |
| May 2027 | [Cagrilintide primary completion](https://sec-api.dev/pdufa/cagrilintide) | NVO | Overweight; Obesity; Type 2 Diabetes | scheduled | "NCT07220759 (Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-12 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07220759)) |
| May 2027 | [CDR132L primary completion](https://sec-api.dev/pdufa/cdr132l) | NVO | Heart Failure | scheduled | "NCT06979375 (A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05-16 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06979375)) |
| May 2027 | [Cagrilintide primary completion](https://sec-api.dev/pdufa/cagrilintide) | NVO | Overweight; Obesity | scheduled | "NCT07745504 (A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-18 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07745504)) |
| Jun to Sep 2027 | [Wegovy (semaglutide) topline data readout](https://sec-api.dev/pdufa/semaglutide) | NVO | Obesity | scheduled | "NCT07639021 (A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-14 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07639021)) |
| Jun to Sep 2027 | [Cagrisema topline data readout](https://sec-api.dev/pdufa/cagrisema) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT07817251 (Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-09 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07817251)) |
| June 2027 | [Cagrisema primary completion](https://sec-api.dev/pdufa/cagrisema) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT07817251 (Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-09 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07817251)) |
| June 2027 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Obesity | scheduled | "NCT07639021 (A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-14 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07639021)) |
| Aug to Nov 2027 | [Etavopivat topline data readout](https://sec-api.dev/pdufa/etavopivat) | NVO | Sickle Cell Disease | scheduled | "NCT06612268 (A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08-27 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06612268)) |
| August 2027 | [Etavopivat primary completion](https://sec-api.dev/pdufa/etavopivat) | NVO | Sickle Cell Disease | scheduled | "NCT06612268 (A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08-27 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06612268)) |
| September 2027 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Cardiovascular Disease | scheduled | "NCT05669755 (REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-01 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05669755)) |
| Sep to Dec 2027 | [Wegovy (semaglutide) topline data readout](https://sec-api.dev/pdufa/semaglutide) | NVO | Cardiovascular Disease | scheduled | "NCT05669755 (REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-01 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05669755)) |
| Sep to Dec 2027 | [Wegovy (semaglutide) topline data readout](https://sec-api.dev/pdufa/semaglutide) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT07415954 (A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-03 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07415954)) |
| September 2027 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT07415954 (A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-03 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07415954)) |
| Oct 2027 to Jan 2028 | [Wegovy (semaglutide) topline data readout](https://sec-api.dev/pdufa/semaglutide) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT07668388 (A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-04 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07668388)) |
| October 2027 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT07668388 (A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-04 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07668388)) |
| Nov 2027 to Feb 2028 | [Wegovy (semaglutide) topline data readout](https://sec-api.dev/pdufa/semaglutide) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT03811561 (A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-07 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03811561)) |
| Nov 2027 to Feb 2028 | [CDR132L topline data readout](https://sec-api.dev/pdufa/cdr132l) | NVO | Heart Failure | scheduled | "NCT06979362 (A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-16 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06979362)) |
| November 2027 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT03811561 (A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-07 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03811561)) |
| November 2027 | [CDR132L primary completion](https://sec-api.dev/pdufa/cdr132l) | NVO | Heart Failure | scheduled | "NCT06979362 (A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-16 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06979362)) |
| Feb to May 2028 | [NNC6019-0001 topline data readout](https://sec-api.dev/pdufa/nnc6019-0001) | NVO | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | scheduled | "NCT06260709 (A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-02-29 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06260709)) |
| Feb to May 2028 | [Wegovy (semaglutide) topline data readout](https://sec-api.dev/pdufa/semaglutide) | NVO | Obesity; Type 2 Diabetes | scheduled | "NCT07564414 (A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-23 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07564414)) |
| Feb to May 2028 | [Wegovy (semaglutide) topline data readout](https://sec-api.dev/pdufa/semaglutide) | NVO | Overweight; Obesity | scheduled | "NCT07770841 (Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-22 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07770841)) |
| February 2028 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Overweight; Obesity | scheduled | "NCT07770841 (Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-22 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07770841)) |
| February 2028 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Obesity; Type 2 Diabetes | scheduled | "NCT07564414 (A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-23 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07564414)) |
| February 2028 | [NNC6019-0001 primary completion](https://sec-api.dev/pdufa/nnc6019-0001) | NVO | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | scheduled | "NCT06260709 (A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-02-29 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06260709)) |
| Jun to Sep 2028 | [Mim8 topline data readout](https://sec-api.dev/pdufa/mim8) | NVO | Haemophilia A; Haemophilia A With Inhibitors | scheduled | "NCT05685238 (A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05685238)) |
| Jun to Sep 2028 | [NNC0487-0111 topline data readout](https://sec-api.dev/pdufa/nnc0487-0111) | NVO | Obesity | scheduled | "NCT07503210 (AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-06-06 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07503210)) |
| Jun to Sep 2028 | [NNC0487-0111 topline data readout](https://sec-api.dev/pdufa/nnc0487-0111) | NVO | Obesity; Overweight; Obstructive Sleep Apnoea | scheduled | "NCT07571109 (AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-26 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07571109)) |
| Jun to Sep 2028 | [Zenagamtide topline data readout](https://sec-api.dev/pdufa/zenagamtide) | NVO | Overweight; Obesity | scheduled | "NCT07720271 (AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-27 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07720271)) |
| June 2028 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Hypertension; Obesity | scheduled | "NCT07919405 (A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-06-01 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07919405)) |
| Jun to Sep 2028 | [Wegovy (semaglutide) topline data readout](https://sec-api.dev/pdufa/semaglutide) | NVO | Hypertension; Obesity | scheduled | "NCT07919405 (A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-06-01 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07919405)) |
| Jun to Sep 2028 | [Zenagamtide topline data readout](https://sec-api.dev/pdufa/zenagamtide) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT07931495 (A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-06-05 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07931495)) |
| June 2028 | [Zenagamtide primary completion](https://sec-api.dev/pdufa/zenagamtide) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT07931495 (A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-06-05 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07931495)) |
| June 2028 | [NNC0487-0111 primary completion](https://sec-api.dev/pdufa/nnc0487-0111) | NVO | Obesity | scheduled | "NCT07503210 (AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-06-06 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07503210)) |
| June 2028 | [NNC0487-0111 primary completion](https://sec-api.dev/pdufa/nnc0487-0111) | NVO | Obesity; Overweight; Obstructive Sleep Apnoea | scheduled | "NCT07571109 (AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-26 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07571109)) |
| June 2028 | [Zenagamtide primary completion](https://sec-api.dev/pdufa/zenagamtide) | NVO | Overweight; Obesity | scheduled | "NCT07720271 (AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-27 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07720271)) |
| June 2028 | [Mim8 primary completion](https://sec-api.dev/pdufa/mim8) | NVO | Haemophilia A; Haemophilia A With Inhibitors | scheduled | "NCT05685238 (A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05685238)) |
| Jul to Oct 2028 | [NNC0487-0111 topline data readout](https://sec-api.dev/pdufa/nnc0487-0111) | NVO | Obesity; Overweight; Obstructive Sleep Apnoea | scheduled | "NCT07571005 (AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07-12 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07571005)) |
| Jul to Oct 2028 | [Zenagamtide topline data readout](https://sec-api.dev/pdufa/zenagamtide) | NVO | Type 2 Diabetes; Cardiovascular Risk | scheduled | "NCT07797335 (AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07-31 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07797335)) |
| Jul to Oct 2028 | [Zenagamtide topline data readout](https://sec-api.dev/pdufa/zenagamtide) | NVO | Type 2 Diabetes; Chronic Kidney Disease | scheduled | "NCT07931547 (A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-07-31 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07931547)) |
| Jul to Oct 2028 | [Wegovy (semaglutide) topline data readout](https://sec-api.dev/pdufa/semaglutide) | NVO | Type 2 Diabetes | scheduled | "NCT07931573 (AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-07-04 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07931573)) |
| Jul to Oct 2028 | [Wegovy (semaglutide) topline data readout](https://sec-api.dev/pdufa/semaglutide) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT07931599 (A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-07-24 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07931599)) |
| July 2028 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Type 2 Diabetes | scheduled | "NCT07931573 (AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-07-04 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07931573)) |
| July 2028 | [NNC0487-0111 primary completion](https://sec-api.dev/pdufa/nnc0487-0111) | NVO | Obesity; Overweight; Obstructive Sleep Apnoea | scheduled | "NCT07571005 (AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07-12 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07571005)) |
| July 2028 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT07931599 (A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-07-24 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07931599)) |
| July 2028 | [Zenagamtide primary completion](https://sec-api.dev/pdufa/zenagamtide) | NVO | Type 2 Diabetes; Cardiovascular Risk | scheduled | "NCT07797335 (AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07-31 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07797335)) |
| July 2028 | [Zenagamtide primary completion](https://sec-api.dev/pdufa/zenagamtide) | NVO | Type 2 Diabetes; Chronic Kidney Disease | scheduled | "NCT07931547 (A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-07-31 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07931547)) |
| Aug to Nov 2028 | [Wegovy (semaglutide) topline data readout](https://sec-api.dev/pdufa/semaglutide) | NVO | Obesity | scheduled | "NCT06780449 (A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-08-28 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06780449)) |
| Aug to Nov 2028 | [NNC0487-0111 topline data readout](https://sec-api.dev/pdufa/nnc0487-0111) | NVO | Obesity; Knee Osteoarthritis (OA) | scheduled | "NCT07481630 (A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-14 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07481630)) |
| Aug to Nov 2028 | [NNC0487-0111 topline data readout](https://sec-api.dev/pdufa/nnc0487-0111) | NVO | Obesity; Overweight; Osteoarthritis, Knee | scheduled | "NCT07509307 (AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-14 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07509307)) |
| Aug to Nov 2028 | [NNC0487-0111 topline data readout](https://sec-api.dev/pdufa/nnc0487-0111) | NVO | Diabetes Mellitus; Overweight; Obesity | scheduled | "NCT07533175 (AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-08-07 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07533175)) |
| August 2028 | [NNC0487-0111 primary completion](https://sec-api.dev/pdufa/nnc0487-0111) | NVO | Diabetes Mellitus; Overweight; Obesity | scheduled | "NCT07533175 (AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-08-07 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07533175)) |
| August 2028 | [NNC0487-0111 primary completion](https://sec-api.dev/pdufa/nnc0487-0111) | NVO | Obesity; Knee Osteoarthritis (OA) | scheduled | "NCT07481630 (A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-14 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07481630)) |
| August 2028 | [NNC0487-0111 primary completion](https://sec-api.dev/pdufa/nnc0487-0111) | NVO | Obesity; Overweight; Osteoarthritis, Knee | scheduled | "NCT07509307 (AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-14 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07509307)) |
| August 2028 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Obesity | scheduled | "NCT06780449 (A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-08-28 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06780449)) |
| Oct 2028 to Jan 2029 | [Wegovy (semaglutide) topline data readout](https://sec-api.dev/pdufa/semaglutide) | NVO | Overweight; Obesity | scheduled | "NCT07668414 (A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10-10 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07668414)) |
| October 2028 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Overweight; Obesity | scheduled | "NCT07668414 (A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10-10 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07668414)) |
| Nov 2028 to Feb 2029 | [Ziltivekimab topline data readout](https://sec-api.dev/pdufa/ziltivekimab) | NVO | Myocardial Infarction | scheduled | "NCT07301034 (A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-14 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07301034)) |
| November 2028 | [Ziltivekimab primary completion](https://sec-api.dev/pdufa/ziltivekimab) | NVO | Myocardial Infarction | scheduled | "NCT07301034 (A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-14 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07301034)) |
| Dec 2028 to Mar 2029 | [Wegovy (semaglutide) topline data readout](https://sec-api.dev/pdufa/semaglutide) | NVO | Obesity; Overweight; Diabetes Mellitus, Type 2 | scheduled | "NCT07400107 (AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-12-19 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07400107)) |
| December 2028 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Obesity; Overweight; Diabetes Mellitus, Type 2 | scheduled | "NCT07400107 (AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-12-19 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07400107)) |
| Jan to Apr 2029 | [Zenagamtide topline data readout](https://sec-api.dev/pdufa/zenagamtide) | NVO | Obesity; Overweight | scheduled | "NCT07668401 (AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-01-11 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07668401)) |
| January 2029 | [Zenagamtide primary completion](https://sec-api.dev/pdufa/zenagamtide) | NVO | Obesity; Overweight | scheduled | "NCT07668401 (AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-01-11 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07668401)) |
| Feb to May 2029 | [NNC0487-0111 topline data readout](https://sec-api.dev/pdufa/nnc0487-0111) | NVO | Overweight; Obesity | scheduled | "NCT07822061 (AMAZE 10: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People in Japan With Excess Body Weight Lose Weight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-02-05 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07822061)) |
| February 2029 | [NNC0487-0111 primary completion](https://sec-api.dev/pdufa/nnc0487-0111) | NVO | Overweight; Obesity | scheduled | "NCT07822061 (AMAZE 10: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People in Japan With Excess Body Weight Lose Weight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-02-05 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07822061)) |
| Mar to Jun 2029 | [Denecimig topline data readout](https://sec-api.dev/pdufa/denecimig) | NVO | Haemophilia A | scheduled | "NCT07830732 (A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-23 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07830732)) |
| March 2029 | [Denecimig primary completion](https://sec-api.dev/pdufa/denecimig) | NVO | Haemophilia A | scheduled | "NCT07830732 (A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-23 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07830732)) |
| Apr to Jul 2029 | [Wegovy (semaglutide) topline data readout](https://sec-api.dev/pdufa/semaglutide) | NVO | Non-alcoholic Steatohepatitis | scheduled | "NCT04822181 (Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-04-25 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04822181)) |
| April 2029 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Non-alcoholic Steatohepatitis | scheduled | "NCT04822181 (Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-04-25 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04822181)) |
| Jun to Sep 2029 | [NNC6019-0001 topline data readout](https://sec-api.dev/pdufa/nnc6019-0001) | NVO | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | scheduled | "NCT07207811 (CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-29 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07207811)) |
| Jun to Sep 2029 | [NNC0487-0111 topline data readout](https://sec-api.dev/pdufa/nnc0487-0111) | NVO | Obesity | scheduled | "NCT07339423 (AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-26 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07339423)) |
| June 2029 | [NNC0487-0111 primary completion](https://sec-api.dev/pdufa/nnc0487-0111) | NVO | Obesity | scheduled | "NCT07339423 (AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-26 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07339423)) |
| June 2029 | [NNC6019-0001 primary completion](https://sec-api.dev/pdufa/nnc6019-0001) | NVO | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | scheduled | "NCT07207811 (CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-29 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07207811)) |
| Jul to Oct 2029 | [NNC0487-0111 topline data readout](https://sec-api.dev/pdufa/nnc0487-0111) | NVO | Obesity; Heart Failure | scheduled | "NCT07567001 (A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-23 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07567001)) |
| July 2029 | [NNC0487-0111 primary completion](https://sec-api.dev/pdufa/nnc0487-0111) | NVO | Obesity; Heart Failure | scheduled | "NCT07567001 (A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-23 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07567001)) |
| Sep to Dec 2029 | [Cagrisema (cagrilintide b and semaglutide i) topline data readout](https://sec-api.dev/pdufa/cagrisema-cagrilintide-b-and-semaglutide-i) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT07282613 (A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-07 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07282613)) |
| September 2029 | [Cagrisema (cagrilintide b and semaglutide i) primary completion](https://sec-api.dev/pdufa/cagrisema-cagrilintide-b-and-semaglutide-i) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT07282613 (A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-07 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07282613)) |
| Mar to Jun 2030 | [Wegovy (semaglutide) topline data readout](https://sec-api.dev/pdufa/semaglutide) | NVO | Overweight; Obesity | scheduled | "NCT07253285 (A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-03-20 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07253285)) |
| March 2030 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Overweight; Obesity | scheduled | "NCT07253285 (A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-03-20 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07253285)) |
| Sep to Dec 2030 | [Zenagamtide topline data readout](https://sec-api.dev/pdufa/zenagamtide) | NVO | Cardiovascular Risk; Obesity | scheduled | "NCT07861100 (A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-09-16 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07861100)) |
| September 2030 | [Zenagamtide primary completion](https://sec-api.dev/pdufa/zenagamtide) | NVO | Cardiovascular Risk; Obesity | scheduled | "NCT07861100 (A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-09-16 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07861100)) |

## Drugs

- [Awiqli (awiqli)](https://sec-api.dev/pdufa/awiqli): type 2 diabetes
- [Cagrilintide](https://sec-api.dev/pdufa/cagrilintide): Overweight, Obesity
- [Cagrisema](https://sec-api.dev/pdufa/cagrisema): Diabetes Mellitus, Type 2
- [Cagrisema (cagrilintide b and semaglutide i)](https://sec-api.dev/pdufa/cagrisema-cagrilintide-b-and-semaglutide-i): Diabetes Mellitus, Type 2, Obesity
- [CDR132L](https://sec-api.dev/pdufa/cdr132l): Heart Failure
- [Alhemo (concizumab)](https://sec-api.dev/pdufa/concizumab): Haemophilia A and B With and Without Inhibitors
- [Alhemo (concizumab-mtci)](https://sec-api.dev/pdufa/concizumab-mtci): For routine prophylaxis to prevent bleeding episodes in hemophilia A and B
- [Dasiglucagon](https://sec-api.dev/pdufa/dasiglucagon): Diabetes Mellitus, Type 1
- [Denecimig](https://sec-api.dev/pdufa/denecimig): haemophilia a in adult and paediatric patients, Haemophilia A
- [Etavopivat](https://sec-api.dev/pdufa/etavopivat): Sickle Cell Disease
- [Icosema](https://sec-api.dev/pdufa/icosema): Type 2 Diabetes
- [Fiasp Penfill (insulin aspart)](https://sec-api.dev/pdufa/insulin-aspart): 
- [Tresiba (insulin degludec)](https://sec-api.dev/pdufa/insulin-degludec): 
- [Xultophy 100/3.6 (insulin degludec; liraglutide)](https://sec-api.dev/pdufa/insulin-degludec-liraglutide): 
- [Awiqli Flextouch (insulin icodec)](https://sec-api.dev/pdufa/insulin-icodec): Diabetes Mellitus, Type 1, Diabetes, Type 2
- [Saxenda (liraglutide)](https://sec-api.dev/pdufa/liraglutide): 
- [Mim8](https://sec-api.dev/pdufa/mim8): Haemophilia A
- [Ndec - oral decitabine-tetrahydrouridine](https://sec-api.dev/pdufa/ndec-oral-decitabine-tetrahydrouridine): Sickle Cell Disease
- [Rivfloza (nedosiran sodium)](https://sec-api.dev/pdufa/nedosiran): 
- [NN1644](https://sec-api.dev/pdufa/nn1644): 
- [NN6705](https://sec-api.dev/pdufa/nn6705): 
- [NNC0487-0111](https://sec-api.dev/pdufa/nnc0487-0111): Obesity, Diabetes Mellitus, Overweight
- [Nnc0487-0111 subcutanous](https://sec-api.dev/pdufa/nnc0487-0111-subcutanous): Type 2 Diabetes (T2D)
- [NNC0519-0130](https://sec-api.dev/pdufa/nnc0519-0130): Diabetes Mellitus, Type 2
- [NNC0662-0419](https://sec-api.dev/pdufa/nnc0662-0419): Overweight
- [NNC6019-0001](https://sec-api.dev/pdufa/nnc6019-0001): Transthyretin Amyloid Cardiomyopathy (ATTR CM)
- [Oral semaglutide](https://sec-api.dev/pdufa/oral-semaglutide): Type 2 Diabetes
- [Ozempic® (ozempic)](https://sec-api.dev/pdufa/ozempic): 
- [PDS290](https://sec-api.dev/pdufa/pds290): 
- [Rybelsus (rybelsus)](https://sec-api.dev/pdufa/rybelsus): type 2 diabetes and established cardiovascular disease and/or chronic kidney disease
- [Semagludtide](https://sec-api.dev/pdufa/semagludtide): Early Alzheimer's Disease
- [Wegovy (semaglutide)](https://sec-api.dev/pdufa/semaglutide): mash in adults with moderate to advanced liver fibrosis, moderate to advanced liver fibrosis, obesity, chronic heart failure, Non-alcoholic Steatohepatitis, Alcohol-related Liver Disease, Chronic Kidney Disease, Overweight
- [Sogroya (somapacitan-beco)](https://sec-api.dev/pdufa/somapacitan-beco): 
- [UBT251](https://sec-api.dev/pdufa/ubt251): type 2 diabetes, Overweight
- [Zenagamtide](https://sec-api.dev/pdufa/zenagamtide): Diabetes Mellitus, Type 2, Cardiovascular Risk, Overweight, Type 2 Diabetes, Obesity
- [Ziltivekimab](https://sec-api.dev/pdufa/ziltivekimab): Heart Failure, Myocardial Infarction, Cardiovascular Risk
- [Ziltivekimab b](https://sec-api.dev/pdufa/ziltivekimab-b): Cardiovascular Risk

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/nvo/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "NVO catalysts: NOVO NORDISK A S PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/nvo/catalysts

```bibtex
@misc{secapidev_companies_nvo_catalysts_20261116,
  title        = {NVO catalysts: NOVO NORDISK A S PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/nvo/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_nvo_catalysts_20261116","title":"NVO catalysts: NOVO NORDISK A S PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/nvo/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
